Health Care · Pharmaceutical Preparations

BHVN Biohaven Ltd. SEC Filings & Insider Trading Activity 2026

company
CIK 193597956 filings
Russell 2000

BHVN at a glance

Biohaven Ltd. (BHVN, SEC CIK 1935979) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 16, 2026 and Form 4 insider filings as recently as September 17, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 28 institutional investment managers tracked by SignalX reported holding Biohaven Ltd. (BHVN) shares worth $620.3 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
28 funds
$620.3M · −1 vs prior quarter
Latest 8-K
Nov 16, 2026
Item 7.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Biopharmaceutical development focused on neurological therapies, notably troriluzole
  • New financing structure: $250M initial senior secured notes plus up to $350M contingent tranches linked to regulatory approvals
  • Strategic shift to revenue-based funding with royalty-like payments of 6.25%+ on global net sales of troriluzole
  • Most notable metric: $250 million proceeds received from First Notes in April 2025 under Note Purchase Agreement
  • Unique feature: Complex milestone, revenue payment caps, and call/put options tied to FDA/EMA approval timelines and sales benchmarks

Risk Factors

  • Key regulatory risk: FDA approval dependency for troriluzole to unlock $150M senior secured notes tranche under April 2025 Note Purchase Agreement
  • Geopolitical/macro threat: Tax provision exposure from profitable US and Ireland subsidiaries, with net deferred tax assets fully reserved against realization
  • Operational risk: One-time $42.7M cash milestone payment to Knopp in January 2026 related to 2025 Additional Consideration under Knopp Amendment
  • Competitive risk: Royalty buyback of $867.5M milestone payments to Knopp reduces future payments but exposes to mid-single digit flat royalty on Kv7 programs
  • Financial risk: Liquidity pressure with net operating loss and $609.4M cash used in operations in 2025 despite $230M cash and $89.2M marketable securities on hand

Management Discussion & Analysis

  • No management outlook, guidance, or key emerging risks mentioned
  • Text focuses on industry data sources, estimates, and trademark notices

AI summary of the BHVN 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly revenue $0, unchanged YoY, with no product sales
  • Net loss $129.3M vs $173.4M YoY, operating margin not meaningful due to no revenue
  • Highest R&D spend: BHV-1400 at $10.1M, lowest: BHV-2100 and BHV-2110 at $(1.2)M
  • Cash and equivalents $95.8M plus marketable securities $65.4M; operating cash use $341.9M year-to-date
  • Outlook: RISE 3 topline results on track for second half of 2026; BHV-7000 enrollment paused under partial clinical hold

Risk Factors

  • New Ono collaboration risk: October 2026 license covers MoDE™ degraders in Japan, South Korea, Taiwan, and ASEAN
  • Most materially updated financial risk: no committed external funding beyond potential SKBP and Ono payments
  • Regulatory and compliance risk: SKBP HSR waiting period expired October 28, 2026, but remaining closing conditions persist
  • Operational risk: SKBP controls development resources for Kv7 products, including opakalim
  • Financial risk: SKBP agreement includes $400.0 million upfront and up to $150.0 million milestone payments at risk

AI summary of the BHVN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 16, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Investor presentation at Jefferies Global Healthcare Conference, London, November 16-19
  • Exhibit 99.1 contains Biohaven’s conference materials, potentially relevant for pipeline and corporate updates

Item EX-99.1: Item EX-99.1

  • November 2026 corporate presentation highlights Biohaven’s protein-degrader platform and broad pipeline across autoimmune disease, epilepsy, pain, oncology, and neurology
  • BHV-1300 Graves’ disease Phase 3 initiated, following preliminary data showing over 80% TSHR autoantibody reduction and hormone normalization within 3 to 5 weeks
Filed Oct 29, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • FDA accepted Vyglxia NDA resubmission for SCA, with advisory committee review and user-fee goal date in 1Q27
  • Ono license provides $80M upfront, up to $20M milestone, and approximately 20% royalties while preserving US, Europe, and China rights

Item 2.02: Results of Operations and Financial Condition

  • Biohaven reported third-quarter financial results for the period ended September 30, 2026
  • Investor-relevant revenue, earnings and cash-flow details are in Exhibit 99.1, the accompanying earnings release
Filed Oct 22, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • FDA accepted Vyglxia resubmission for SCA review, signaling the application cleared completeness requirements
  • First-quarter 2027 user fee goal date, establishing the next major regulatory catalyst

AI summaries of BHVN 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for BHVN

Don't miss the next BHVN filing

  • Alerts as it files. A push when BHVN files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut BHVN, by share count.
  • Ask anything. An AI agent that reads every BHVN filing and answers with sources.

BHVN alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Gentile KimberlyASep 15, 2026-
HUGIN ROBERT JAApr 28, 2026-
Heffernan Michael ThomasAApr 28, 2026-
Bailey GregoryAApr 28, 2026-
Mehta KishanAApr 28, 2026-
CHILDS JOHN WAApr 28, 2026-
GREGORY JULIA PAApr 28, 2026-
Antonijevic IrinaAApr 28, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$436.1M-$885.1M-$745.4M
Net Income-$408.2M-$846.4M-$738.8M
Balance Sheet
Total Assets$513.2M$615.1M$451.4M
Equity-$423.4M$52.1M
ROE--199.9%-1418.8%
Per Share
EPS$-5.73$-9.28$-6.86
Cash Flow
Operating CF-$331.7M-$582.5M-$609.4M
CapEx$3.0M$4.0M$715K

Source: XBRL data in Biohaven Ltd. (BHVN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate BHVN share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
BHVN shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202628$620.3M
Q2 202629$723.2M
Q1 202629$362.7M
Q4 202524$466.3M
Q3 202526$487.6M
Q2 202526$505.2M
Q1 202527$553.9M
Q4 202423$702.7M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 212 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

BHVN filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 16, 2026Analysis-
8-KOct 29, 2026Analysis-
10-QOct 29, 2026Analysis
8-KOct 22, 2026Analysis-
8-KOct 15, 2026Analysis-
4Sep 17, 2026--
8-KSep 10, 2026Analysis-
8-KAug 26, 2026Analysis-
SC 13GAug 14, 2026-
8-KAug 10, 2026Analysis-
10-QAug 10, 2026Analysis
8-KAug 7, 2026Analysis-
8-KJul 9, 2026Analysis-
8-KMay 27, 2026Analysis
8-KMay 5, 2026Analysis-
8-KMay 4, 2026--
8-KMay 4, 2026Analysis-
10-QMay 4, 2026Analysis
4Apr 30, 2026--
4Apr 30, 2026--
4Apr 30, 2026--
4Apr 30, 2026--
4Apr 30, 2026--
4Apr 30, 2026--
4Apr 30, 2026--

Related Health Care companies

All Health Care →

BHVN SEC filings: frequently asked questions

Which institutions hold BHVN stock?

As of September 30, 2026, the largest Biohaven Ltd. (BHVN) holders among the 13F filers tracked by SignalX were BlackRock ($172.9 million), State Street Corp ($91.8 million), Bank of America Corp ($54.4 million), AQR Capital Management ($54.1 million), Goldman Sachs Group ($49.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What are the main risks in BHVN's latest 10-K?

In the 10-K filed March 2, 2026, Biohaven Ltd. (BHVN) flagged: Key regulatory risk: FDA approval dependency for troriluzole to unlock $150M senior secured notes tranche under April 2025 Note Purchase Agreement. Geopolitical/macro threat: Tax provision exposure from profitable US and Ireland subsidiaries, with net deferred tax assets fully reserved against realization. (AI summary of the Risk Factors section.)

What did BHVN report in its latest 8-K?

Biohaven Ltd. (BHVN) filed an 8-K on November 16, 2026 reporting Item 7.01 (Regulation FD Disclosure). Investor presentation at Jefferies Global Healthcare Conference, London, November 16-19.

What are the latest BHVN SEC filings?

Biohaven Ltd. (BHVN) filed its latest 10-K annual report on March 2, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 16, 2026 and a Form 4 insider filing on September 17, 2026.

What is BHVN's SEC CIK number?

Biohaven Ltd. (BHVN)'s SEC Central Index Key (CIK) is 1935979. EDGAR lists every BHVN filing under that number.

Ask anything about BHVN

The research agent reads BHVN's filings, financials, insider trades and 13F holders, then answers with sources.